Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with groundbreaking discoveries, cutting-edge research, and influential biotech ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

New Century Financial Group LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 25.1% during the 3rd quarter, according to its most recent disclosure with ...

Governor Maura Healey on Tuesday announced $21.4 million in tax incentives for life sciences companies that are expected to create 1,155 jobs in the state.

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$855 Current... BOSTON, October 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq ...